Findings may help guide clinicians and policymakers in balancing the risks and benefits of stimulant prescribing in adolescent populations, according to the study authors. Between 2005 and 2023, ...

In this paper, we provide several cases of human bite injuries, juxtaposed with cases of bite injuries from common animals. Bite injuries are a significant problem in the United States. Discriminating ...

Back-to-school season impacts children's mental health. Discover strategies for parents to support emotional well-being and resilience in elementary students.

The indication approved is for children aged 6 years and older who weigh at least 45 kg (99 lbs) for the preventive treatment of episodic migraine.

Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head back to school.

Richard Auchus, MD, PhD, highlights data showing that crinecerfont use in children with CAH can improve metabolic outcomes.

An expert discusses advancements in the management of atopic dermatitis, emphasizing early recognition, updated nonsteroidal treatments, accurate differential diagnosis, and the importance of ...

An expert discusses the benefits and risks of topical corticosteroids (TCS) and calcineurin inhibitors in atopic dermatitis (AD) treatment, highlighting patient concerns about long-term adverse ...

An expert discusses the formal diagnostic criteria and diverse clinical presentations of atopic dermatitis, emphasizing patient-centered assessment, challenges in distinguishing it from similar ...

Suzanne Hollander, MS, RD, LDN; and Timothy Tramontana, MD, offer thoughts on newly FDA-approved sepiapterin for PKU. On July 28, 2025, the FDA approved PTC Therapeutics' sepiapterin (Sephience) to ...

On July 30, 2025, AbbVie announced positive and topline data from the phase 3 UP-AA clinical program (NCT06012240), in which upadacitinib (Rinvoq) (15 mg and 30 mg) demonstrated that 44.6% and 54.3% ...